Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions.
[OBJECTIVES] Geographic health disparities persist across the United States, with substantial variations in health outcomes between regions.
APA
Jansen JP, Douglas MP, Phillips KA (2026). Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 29(1), 34-45. https://doi.org/10.1016/j.jval.2025.07.025
MLA
Jansen JP, et al.. "Combining Simulation Model-Based Outcomes With County-Level Data for Geographic Health Equity Impact Evaluations of New Interventions.." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, vol. 29, no. 1, 2026, pp. 34-45.
PMID
40780515
Abstract
[OBJECTIVES] Geographic health disparities persist across the United States, with substantial variations in health outcomes between regions. Evaluating how emerging health technologies might affect these disparities is crucial for developing equitable health policies. This article introduces an approach for geographic health equity impact evaluation by combining predicted outcomes by equity-relevant subgroup from a simulation model with US county-level data on subgroup proportions.
[METHODS] The approach involves the following steps: (1) create a data set with county-level information on equity-relevant factors and lifetime risk of the target indication; (2) estimate quality-adjusted life-years (QALYs) and costs with and without the intervention for different combinations of equity-relevant factors with the simulation model; (3) calculate expected and incremental QALYs in target population, incremental net health benefits per 100 000 general population, and quality-adjusted life expectancy at birth without and with liquid biopsy for each county based on its distribution of equity-relevant factors and step 2 estimates; and (4) quantify inequality in QALYs and quality-adjusted life expectancies between counties with and without the technology and the corresponding health equity impact.
[RESULTS] We illustrate the approach using liquid biopsy for first-line treatment in non-small cell lung cancer. Future applications should incorporate more detailed information on the equity-relevant groups by county.
[CONCLUSIONS] Combining simulation model outcomes with county-level data on equity-relevant subgroups provides a novel approach for health equity impact evaluations of new interventions. It facilitates examining how introducing a new health technology can affect geographic disparities in health and can help identify areas that may benefit most from a new intervention.
[METHODS] The approach involves the following steps: (1) create a data set with county-level information on equity-relevant factors and lifetime risk of the target indication; (2) estimate quality-adjusted life-years (QALYs) and costs with and without the intervention for different combinations of equity-relevant factors with the simulation model; (3) calculate expected and incremental QALYs in target population, incremental net health benefits per 100 000 general population, and quality-adjusted life expectancy at birth without and with liquid biopsy for each county based on its distribution of equity-relevant factors and step 2 estimates; and (4) quantify inequality in QALYs and quality-adjusted life expectancies between counties with and without the technology and the corresponding health equity impact.
[RESULTS] We illustrate the approach using liquid biopsy for first-line treatment in non-small cell lung cancer. Future applications should incorporate more detailed information on the equity-relevant groups by county.
[CONCLUSIONS] Combining simulation model outcomes with county-level data on equity-relevant subgroups provides a novel approach for health equity impact evaluations of new interventions. It facilitates examining how introducing a new health technology can affect geographic disparities in health and can help identify areas that may benefit most from a new intervention.
MeSH Terms
Humans; Health Equity; Quality-Adjusted Life Years; United States; Computer Simulation; Healthcare Disparities; Health Status Disparities; Cost-Benefit Analysis
같은 제1저자의 인용 많은 논문 (2)
- The potential survival gain and cost-effectiveness of circulating tumor DNA-guided treatment switching in advanced non-small cell lung cancer: A simulation modeling study.
- The Health Inequality Impact of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer in the United States: A Distributional Cost-Effectiveness Analysis.